# A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

> **NCT01223222** · PHASE2 · COMPLETED · sponsor: **Lytix Biopharma AS** · enrollment: 24 (estimated)

## Conditions studied

- Gram-positive, Skin Infections
- Mild Eczema/Dermatoses
- Atopic Dermatitis

## Interventions

- **DRUG:** LTX-109

## Key facts

- **NCT ID:** NCT01223222
- **Lead sponsor:** Lytix Biopharma AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2011-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01223222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01223222, "A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01223222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*